解脲支原体感染新生儿的临床特征分析

Clinical characteristics analysis of newborns with ureaplasma urealyticum

摘要

目的 分析解脲支原体感染新生儿的临床特征,为临床诊治提供依据。方法 回顾性分析柳州市妇幼保健院新生儿科病房2019年6月至2021年6月收治的94例解脲支原体感染新生儿的临床资料,根据胎龄分为早产儿组和足月儿组,对比两组患儿的母亲基本信息、实验室检查结果及合并症,并评估不同大环内酯类药物治疗的有效性及安全性。结果 呼吸道解脲支原体发生率为14.95%,多见于早产儿特别是极早产儿.早产儿组以胎膜早破最为常见,足月儿组以产前发热最为常见.两组患儿的血常规结果无显著性差异(P>0.05),早产儿组较足月儿组更易发生病理性黄疸、新生儿肺炎、新生儿呼吸窘迫综合征(NRDS)和支气管肺发育不良(BPD)(χ²=8.002、15.499、12.185、5.406,均P<0.05).阿奇霉素和红霉素治疗早产儿解脲支原体感染的有效率分别为81.82%和75.00%,不同药物治疗组的住院时间、吸氧时间、有创呼吸机使用时间、生后即插管情况、坏死性小肠结肠炎(NEC)、BPD、早产儿视网膜病变(ROP)、转阴率差异无统计学意义(t/χ²=-0.736、-0.132、1.754、0.509、0.157、0.242、2.070、0.001,均P>0.05)。结论 解脲支原体对新生儿及其母亲均有一定影响.采用阿奇霉素或红霉素治疗解脲支原体感染的早产儿,两种药物的疗效无显著性差异.

Abstract

Objective To analyze the clinical characteristics of newborns infected with ureaplasma urealyticum, providing a basis for clinical diagnosis and treatment. Methods A retrospective analysis of the clinical data of 94 newborns with ureaplasma urealyticum infection admitted to the department of neonatology of Liuzhou Maternity and Child Health Hospital from June 2019 to June 2021 was conducted. They were divided into preterm and term groups according to their gestational age. The basic information of the mothers, laboratory examination results, and complications of the two groups of patients were compared. And the effectiveness and safety of different macrolide antibiotics in the treatment were evaluated. Results The incidence of respiratory tract ureaplasma urealyticum was 14.95%, more common in premature infants, especially extremely preterm infants. Premature infants are most commonly associated with premature rupture of membranes, while term infants are most commonly associated with antenatal fever. There was no significant difference in blood routine results between the two groups of patients (P>0.05). Premature infants are more prone to pathological jaundice, neonatal pneumonia, neonatal respiratory distress syndrome (NRDS), and bronchopulmonary dysplasia (BPD) than term infants (χ²=8.002, 15.499, 12.185 and 5.406, respectively, all P<0.05). The effective rates of azithromycin and erythromycin for the treatment of preterm infants with ureaplasma urealyticum infection were 81.82% and 75.00%, respectively. There was no significant difference in the hospitalization time, oxygen therapy time, duration of invasive ventilation, postnatal intubation, necrotizing enterocolitis (NEC), BPD, retinopathy of prematurity (ROP), and conversion rate between different drug treatment groups (t/χ²=-0.736, -0.132, 1.754, 0.509, 0.157, 0.242, 2.070 and 0.001, respectively, all P>0.05). Conclusion Ureaplasma urealyticum has certain effects on newborns and their mothers, and there is no significant difference in efficacy between azithromycin and erythromycin in the treatment of premature infants with ureaplasma urealyticum infection.

关键词

解脲支原体 / 新生儿 / 阿奇霉素 / 红霉素

Key words

ureaplasma urealyticum / newborns / azithromycin / erythromycin

参考文献

[1] 郑淮武, 万胜明, 邱素清. 解脲支原体与新生儿疾病关系的研究进展[J]. 中华新生儿科杂志, 2019, 34(3): 234-238.

[2] Silwedel C, Speer CP, Härtel C, et al. Ureaplasma-driven neuroinflammation in neonates: assembling the puzzle pieces[J]. Neonatology, 2020, 117(6): 665-672.

[3] 黄海溶, 李晓珍, 黄元华. 解脲支原体感染与不良妊娠结局的相关分析[J]. 中国妇幼健康研究, 2014, 25(1): 38-39.

[4] Viscardi R M, Kallapur S G. Role of ureaplasma respiratory tract colonization in bronchopulmonary dysplasia pathogenesis: current concepts and update[J]. Clin Perinatol, 2015, 42(4): 719-738.

[5] 张盼盼, 高湛, 毋蓓蓓, 等. 解脲支原体和衣原体感染与胎膜早破及妊娠结局之间的临床分析[J]. 世界复合医学, 2018, 4(4): 72-74.

[6] 周鹏翔, 周薇, 王晓玲, 等. «儿科阿奇霉素注射使用的快速建议指南»解读[J]. 临床药物治疗杂志, 2019, 17(7): 39-45.

[7] Thevin P, Curti C, Benech A, et al. Low-dose erythromycin in pediatrics: formulation and stability of 20 mg hard gelatin capsules[J]. PLoS One, 2023, 18(2): e0282164.

[8] 邵少梅, 叶鸿瑁, 丘小汕. 实用新生儿学[M].第5版. 北京: 人民卫生出版社, 2019: 460.

[9] Kemper A R, Newman T B, Slaughter J L, et al. Clinical practice guideline revision: management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation[J]. Pediatrics, 2022, 150(3): e2022058859.

[10] 邵少梅, 叶鸿瑁, 丘小汕. 实用新生儿学[M].第5版. 北京: 人民卫生出版社, 2019: 582-583.

[11] 邵少梅, 叶鸿瑁, 丘小汕. 实用新生儿学[M].第5版. 北京: 人民卫生出版社, 2019: 575-578.

[12] 中华医学会眼科学分会眼底病学组, 中国医师协会眼科医师分会眼底病专委会. 中国早产儿视网膜病变分类和治疗专家共识(2023年)[J]. 中华眼底病杂志, 2023, 39(9): 720-727.

[13] Chu A, de St Maurice A, Sim M S, et al. Neonatal mycoplasma and ureaplasma infections[J]. Pediatr Ann, 2020, 49(7): e305-e312.

[14] 胡海燕. 新生儿呼吸道解脲支原体的感染情况与药敏分析[J]. 中国卫生检验杂志, 2021, 31(2): 165-167.

[15] Wei H L, Xing Y, Zhou Y, et al. [Clinical characteristics of ureaplasma urealyticum pneumonia in preterm infants with gestational age less than 32 weeks][J]. Zhonghua Yu Fang Yi Xue Za Zhi, 2021, 55(2): 239-244.

[16] 范旭方, 夏磊, 霍婉莹, 等. 极低出生体重早产儿宫内解脲支原体感染的临床特征分析[J]. 中华新生儿科杂志(中英文), 2023, 38(5): 262-266.

[17] 郑淮武, 张丽娟, 温清华, 等. 气道分泌物解脲支原体阳性早产儿临床特征分析[J]. 中华新生儿科杂志(中英文), 2023, 38(9): 545-549.

[18] Resch B, Gutmann C, Reiterer F, et al. Neonatal ureaplasma urealyticum colonization increases pulmonary and cerebral morbidity despite treatment with macrolide antibiotics[J]. Infection, 2016, 44(3): 323-327.

[19] Oeser C, Pond M, Butcher P, et al. PCR for the detection of pathogens in neonatal early onset sepsis[J]. PLoS One, 2020, 15(1): e0226817.

[20] Sun T, Fu J. Analysis of the clinical features of intrauterine ureaplasma urealyticum infection in preterm infants: a case-control study[J]. Front Pediatr, 2021, 9: 774150.

[21] 张翠兰, 连燕燕. 解脲支原体感染对妊娠结局及围生儿的影响[J]. 中国医药指南, 2013, 11(3): 2.

[22] Beeton M L, Spiller O B. Antibiotic resistance among Ureaplasma spp. isolates: cause for concern? [J]. J Antimicrob Chemother, 2017, 72(2): 330-337.

[23] Razak A, Alshehri N. Azithromycin for preventing bronchopulmonary dysplasia in preterm infants: A systematic review and meta-analysis[J]. Pediatr Pulmonol, 2021, 56(5): 957-966.

[24] Viscardi R M, Terrin M L, Magder L S, et al. Randomised trial of azithromycin to eradicate ureaplasma in preterm infants[J]. Arch Dis Child Fetal Neonatal Ed, 2020, 105(6): 615-622.

基金资助

广西柳州科技局科技计划自筹项目(2020NBAB0115)